FGP
INSM icon

Freestone Grove Partners’s Insmed INSM Stock Holding History

Freestone Grove Partners’s Portfolio INSM Stock Details INSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-36,200
Closed -$6.3M – 1083
2025
Q4 		$6.3M Buy
+36,200
New +$6.61M 0.05% 333
2025
Q1 		– Sell
-7,583
Closed -$524K – 687
2024
Q4 		$524K Buy
+7,583
New +$546K 0.01% 372

Other funds holding INSM

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Freestone Grove Partners's INSM Position: Q1 2026 in Review

Freestone Grove Partners sold out of Insmed (INSM) in Q1 2026, closing a stake of 36,200 shares — an estimated $6.3M sold.

Freestone Grove Partners first reported a position in INSM in Q4 2024 and held it in 2 quarters. The position peaked at $6.3M in Q4 2025. 669 funds tracked by Wall St. Rank hold INSM as of Q1 2026.

  • Freestone Grove Partners reported no remaining Insmed position as of Q1 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 36,200 Insmed shares in Q1 2026, an estimated $6.3M.
  • Freestone Grove Partners first reported a position in Insmed in Q4 2024 and held it in 2 quarters.
  • Freestone Grove Partners's Insmed position peaked at $6.3M in Q4 2025.
  • 669 funds tracked by Wall St. Rank held Insmed as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.